Kolon TissueGene (950160) is attracting investor attention as it extends its strength for the fourth consecutive trading day.

On the KOSDAQ market on the 5th, Kolon TissueGene closed at 18,660 won, up 17.21% (2,740 won) from the previous trading day. During the session, the stock surged to as high as 20,650 won, recovering the 20,000-won level for the first time in about two weeks since July 23.

Analysts note that the share price, which had plunged following the announcement of the Phase 3 clinical trial results for TG-C, a U.S. osteoarthritis treatment, last month, is showing a recovery trend driven by a technical rebound and an inflow of bargain-hunting buyers. The stock has recorded gains for four consecutive trading days, continuing its short-term rebound.

The broader domestic stock market also showed strength on the same day. KOSPI rose 239.31 points (3.76%) from the previous trading day to 6,598.26, and KOSDAQ gained 18.87 points (2.41%) to 799.59, reflecting improving investor sentiment.

With the current rebound continuing, market attention is focused on whether the stock can stabilize at the 20,000-won level and sustain its additional recovery. Interest is also concentrated on the market trend on the 6th.

[※ This article is not intended to solicit investment, and the final decision and responsibility for investments lie with the investor.]